Citation Tools
PDFCurrent controversy
Equipoise, standard of care and consent: responding to the authorisation of new COVID-19 treatments in randomised controlled trials
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- Equipoise, standard of care and consent: responding to the authorisation of new COVID-19 treatments in randomised controlled trials
Other content recommended for you
- Platform adaptive trial of novel antivirals for early treatment of COVID-19 In the community (PANORAMIC): protocol for a randomised, controlled, open-label, adaptive platform trial of community novel antiviral treatment of COVID-19 in people at increased risk of more severe disease
- Comparative effectiveness of sotrovimab and molnupiravir for prevention of severe covid-19 outcomes in patients in the community: observational cohort study with the OpenSAFELY platform
- Two new oral antivirals for covid-19: ▼molnupiravir and ▼nirmatrelvir plus ritonavir
- Learning health systems, clinical equipoise and the ethics of response adaptive randomisation
- E-therapies in England for stress, anxiety or depression: what is being used in the NHS? A survey of mental health services
- Evolving role of novel COVID-19 Medicine Delivery Units
- Platform Randomised trial of INterventions against COVID-19 In older peoPLE (PRINCIPLE): protocol for a randomised, controlled, open-label, adaptive platform, trial of community treatment of COVID-19 syndromic illness in people at higher risk
- Early development of primary care networks in the NHS in England: a qualitative mixed-methods evaluation
- OpenSAFELY: impact of national guidance on switching anticoagulant therapy during COVID-19 pandemic
- Trends, variation, and clinical characteristics of recipients of antiviral drugs and neutralising monoclonal antibodies for covid-19 in community settings: retrospective, descriptive cohort study of 23.4 million people in OpenSAFELY